Compare IGIC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | OPK |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 921.2M |
| IPO Year | 2019 | 2011 |
| Metric | IGIC | OPK |
|---|---|---|
| Price | $23.08 | $1.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $28.00 | $2.03 |
| AVG Volume (30 Days) | 63.3K | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $2.54 | $4.76 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.82 | $1.10 |
| 52 Week High | $26.98 | $1.81 |
| Indicator | IGIC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 42.99 |
| Support Level | $22.72 | $1.13 |
| Resistance Level | $24.09 | $1.27 |
| Average True Range (ATR) | 0.73 | 0.04 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 28.51 | 45.83 |
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.